An epoxomicin derivate with potential antineoplastic activity. It irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S proteasome, an enzyme responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.

KEYWORDS: Carfilzomib | Supplier | Proteasome inhibitor | PR-171 | PR171 | PR 171 | CT-CARF | CAS [868540-17-4] | Non Selective (Ubiquitin peptides) | Inhibitor